{"drugs":["Cystaran","Cysteamine Hydrochloride"],"mono":{"0":{"id":"930152-s-0","title":"Generic Names","mono":"Cysteamine Hydrochloride"},"1":{"id":"930152-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930152-s-1-4","title":"Adult Dosing","mono":"<b>Cystinosis, Corneal cysteine crystal accumulation:<\/b> INSTILL 1 drop of 0.44% ophthalmic solution in each eye every waking hour "},"1":{"id":"930152-s-1-5","title":"Pediatric Dosing","mono":"<b>Cystinosis, Corneal cysteine crystal accumulation:<\/b> INSTILL 1 drop of 0.44% ophthalmic solution in each eye every waking hour "},"3":{"id":"930152-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Cystinosis, Corneal cysteine crystal accumulation<br\/>"}}},"3":{"id":"930152-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930152-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930152-s-3-10","title":"Precautions","mono":"<ul><li>contamination of dropper tip may occur; do not touch to eyelids or other areas and keep bottle tightly closed when not in use<\/li><li>intracranial hypertension, benign, has been reported; all patients were receiving oral therapy or concomitant oral and ophthalmic therapy<\/li><li>to report suspected adverse reactions, contact the US Food and Drug Administration (FDA) at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930152-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Cysteamine: C (FDA)<\/li><li>Cysteamine: B3 (AUS)<\/li><\/ul>"},{"id":"930152-s-3-12","title":"Breast Feeding","mono":"Cysteamine: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930152-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Neurologic:<\/b>Headache (greater than or equal to 10%)<\/li><li><b>Ophthalmic:<\/b>Eye irritation, Pain in eye, Photophobia (greater than or equal to 10%), Red eye (greater than or equal to 10%), Visual field defect (greater than or equal to 10%)<\/li><\/ul><b>Serious<\/b><br\/><b>Neurologic:<\/b>Pseudotumor cerebri<br\/>"},"6":{"id":"930152-s-6","title":"Drug Name Info","sub":{"0":{"id":"930152-s-6-17","title":"US Trade Names","mono":"Cystaran<br\/>"},"2":{"id":"930152-s-6-19","title":"Class","mono":"Ophthalmologic Agent<br\/>"},"3":{"id":"930152-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930152-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930152-s-7","title":"Mechanism Of Action","mono":"Cysteamine hydrochloride reduces corneal cystine crystal accumulation by converting cystine to cysteine and cysteine-cysteamine mixed disulfides <br\/>"},"9":{"id":"930152-s-9","title":"Administration","mono":"<b>Ophthalmic<\/b><br\/>remove contact lenses prior to administration; may reinsert 15 minutes following administration <br\/>"},"10":{"id":"930152-s-10","title":"Monitoring","mono":"decrease in corneal cystine crystal accumulation indicates efficacy<br\/>"},"11":{"id":"930152-s-11","title":"How Supplied","mono":"<b>Cystaran<\/b><br\/>Ophthalmic Solution: 6.5 MG\/ML<br\/>"}}}